Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to
assemble and peer-review its pathway modules. The integration of ORCID within Reactome
enables us to meet a key challenge with authoring, curating and reviewing biological
information by incentivizing and crediting the external experts that contribute their
expertise and time to the Reactome curation process. More information is available at
ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please
forward this information to us and we will update your Reactome pathway records.
Details on Person Activated plasma kallikrein binds to alpha2-macroglobulin (S...
| Class:Id | Summation:158348 |
|---|
| _displayName | Activated plasma kallikrein binds to alpha2-macroglobulin (S... |
|---|
| _timestamp | 2026-02-24 18:57:20 |
|---|
| created | [InstanceEdit:158298] D'Eustachio, P, 2005-01-20 14:44:36 |
|---|
| literatureReference | [LiteratureReference:158405] Distribution of plasma kallikrein between C-1 inactivator and alpha 2-macroglobulin in plasma utilizing a new assay for alpha 2-macroglobulin-kallikrein complexes
[LiteratureReference:158326] Primary structure of human alpha 2-macroglobulin. V. The complete structure.
[LiteratureReference:9983509] Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen |
|---|
| modified | [InstanceEdit:167229] D'Eustachio, P, 2005-10-13 14:50:40
[InstanceEdit:9983510] Shamovsky, Veronica, 2026-02-24 |
|---|
| text | Activated plasma kallikrein binds to alpha2-macroglobulin (Sottrup-Jensen L et al. 1984), forming a stable and enzymatically inactive complex. Under normal conditions in vivo, this reaction is estimated to account for approximately 16% of kallikrein inactivation, whereas C1 inhibitor (C1INH) is responsible for the majority of inhibition (Harpel PC et al. 1985). Earlier studies by Schapira M et al. suggest that C1INH accounts for 42% of plasma kallikrein inhibition, while α2-macroglobulin contributes about 48% (Schapira M et al., 1981). |
|---|
| (summation) | [Reaction:158340] kallikrein + alpha2-macroglobulin -> kallikrein:alpha2-macrogloulin [Homo sapiens] |
|---|
|
[Change default viewing format]
|
No pathways have been reviewed or authored by Activated plasma kallikrein binds to alpha2-macroglobulin (S... (158348)
